盘点:肿瘤免疫疗法新进展

2017-08-20 MedSci MedSci原创

免疫治疗是指通过免疫系统达到对抗癌症目的的治疗方式,也是生物治疗的一种,早就被医学界广泛的普及使用,尤其是在肿瘤治疗领域。这里梅斯小编整理了近期关于肿瘤免疫研究领域的最新进展与大家一同分享。【1】地西他滨帮助免疫疗法突破瓶颈圣裘德儿童医院免疫学家们发现了免疫细胞T细胞如何变得“筋疲力尽”,无法完成抵御外部细菌,癌细胞以及病毒侵入工作的原理,这一发现很重要,因为免疫疗法有时对癌症患者无反应,或者癌症

免疫治疗是指通过免疫系统达到对抗癌症目的的治疗方式,也是生物治疗的一种,早就被医学界广泛的普及使用,尤其是在肿瘤治疗领域。这里梅斯小编整理了近期关于肿瘤免疫研究领域的最新进展与大家一同分享。

【1】地西他滨帮助免疫疗法突破瓶颈

圣裘德儿童医院免疫学家们发现了免疫细胞T细胞如何变得“筋疲力尽”,无法完成抵御外部细菌,癌细胞以及病毒侵入工作的原理,这一发现很重要,因为免疫疗法有时对癌症患者无反应,或者癌症易复发,这可能都是T细胞疲劳造成的结果。在此次研究中,科学家们发现,已经在使用的化疗药物可以扭转T细胞的疲劳。这一发现为发展和壮大免疫疗法提供了全新的途径,研究报告发表于近期的《细胞》杂志上,在报道中,研究人员详细解释了解释免疫疗法失败的原因。

【2】肿瘤基因修复缺陷使免疫疗法更有效

来自约翰霍普金斯医学院的研究人员们进行了为期三年的扩大临床试验,参与者为包括直结肠癌在内的12种不同的癌症,这些癌症都存在所谓的“错配修复基因缺陷”,在实验过程中,研究人员发现,半数患者对抗癌药物派姆单抗(pembrolizumab)有反应。基于此次研究的发现,美国食品和药品管理局批准扩大抗癌药派姆单抗的适用范围。研究人员表示,他们找到证据可以证明免疫反应与癌症中存在的基因突变紧密相连。

【3】逆转肿瘤组织中的调节性T细胞对于促进免疫疗法至关重要

调节性T细胞(Tregs)的特征在于它们表达的转录因子Foxp3,分泌抑制炎症的IL10细胞激素,从而维持免疫系统的动态平衡并防止过度的组织损伤。缺乏功能性Treg群体的人会发生自身的过免疫疾病。虽然调节性T细胞对于限制自身过免疫反应是有益的,但是它们可能通过抑制免疫反应从而妨碍对抗肿瘤的免疫疗法。虽然靶向的抑制调节性T细胞可能是有效的治疗方法,但是同时也会影响外周Treg数量从而可能导致危及生命的自身免疫或炎症并发症。因此,有针对性地选择性地破坏肿瘤内调节性T细胞对于开发免疫疗法至关重要。新的一项研究揭示了如何有效的靶向改变肿瘤内部调节型T细胞,使之转变为抑制肿瘤的T细胞,对于抗癌的免疫疗法至关重要。通过降低文章描述的Nrp1基因的表达也许能够成为未来有效的新目标。

【4】免疫球蛋白新抗原有望成为淋巴瘤免疫疗法的新靶点

肿瘤体细胞突变可以产生区别恶性细胞与正常细胞的新抗原。然而,新抗原的个性化鉴定和验证仍然是一个重大的挑战。在此,研究人员利用整合基因组学和蛋白组学的方法在人类套细胞淋巴瘤中进行肿瘤抗原肽的筛选,最终发现了新抗原。研究人员分离了对免疫球蛋白衍生的新抗原具有特异性的循环CD4 + T細胞,发现这些细胞可以介导自体淋巴细胞的杀伤。这些结果表明,MHC的分离,肽段的鉴定及基因组测序联用为肿瘤新抗原的发现提供了一个有效的平台。该方法在人类淋巴瘤中的应用说明免疫球蛋白新抗原可作为淋巴瘤免疫疗法的新靶点。

【5】组合免疫疗法治疗雄激素抵抗性前列腺癌可能有效

用雄激素阻断治疗晚期前列腺癌患者的一部分患者群体往往会经历癌症的复发,病情往往发展成为致死的转移性雄激素抵抗前列腺癌(mCRPC)。在一个患有各种癌症的病例群体中,利用细胞毒性T淋巴细胞相关蛋白-4抗体或者程序性细胞死亡-1/程序性细胞死亡-1-配体-1(PD1/PD-L1)抗体的免疫检查点阻断疗法能够产生持久的治疗反应。然而,mCRPC却表现出对免疫检查点阻断疗法不断更新的抗性,这种现象促使了研究人员利用定点疗法来克服抗性的探索和研究。最近,研究人员对组合免疫疗法进行了探索。利用多重激酶抑制子,如卡博替尼和BEZ235对mCRPC浸润的MDSCs定点治疗同样只产生了轻微程度的抗肿瘤活性。但是,当免疫检查点阻断和定点MDSC疗法组合运用时,初始的和转移性CRPC展示了强烈的协同作用。由此,可以推论的是,组合疗法的效果是得益于白细胞介素受体拮抗体的上调和前列腺癌细胞分泌的调控MDSC细胞激素的抑制。这些结果阐明了一个临床治疗途径假设,即利用免疫检查点阻断和定点MDSC疗法的组合来对mCRPC进行治疗。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (12)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=236073, encodeId=d16a2360e3a2, content=前沿, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/03/19/68358be9323aa8e32edd53bfd17742f1.jpg, createdBy=5a191960665, createdName=1e135751m36(暂无匿称), createdTime=Tue Aug 22 17:49:05 CST 2017, time=2017-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521482, encodeId=5e7715214823e, content=<a href='/topic/show?id=0e108281e8f' target=_blank style='color:#2F92EE;'>#肿瘤免疫疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82817, encryptionId=0e108281e8f, topicName=肿瘤免疫疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=995711357332, createdName=drwjr, createdTime=Tue Aug 22 09:46:00 CST 2017, time=2017-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235692, encodeId=bbed23569209, content=免疫疗法有时对癌症患者无反应,或者癌症易复发,这可能都是T细胞疲劳造成的结果, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Mon Aug 21 13:03:23 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235669, encodeId=adfb2356692e, content=免疫学有可能的, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Mon Aug 21 11:38:59 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235660, encodeId=4923235660d9, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuCkPCv9CVFBmWOibyBArQwSeQLxvxz9OaumlaSUZjfCWTxbXduhuG2xCJUPs1nB9nd4gxZknH7IZj/0, createdBy=52281985209, createdName=damiao93, createdTime=Mon Aug 21 10:38:11 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235625, encodeId=54fc23562573, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM7GibvIBibibnnnvpajk2stlDF5oichYahI6Bia8uxeTBFoPbdoHWebyXf9eal9FNgUF2lNcrwoZicM3BvQ/0, createdBy=a3742066385, createdName=戒馋,懒,贪, createdTime=Mon Aug 21 08:13:15 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235601, encodeId=cfe8235601ab, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Mon Aug 21 07:36:59 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235596, encodeId=2c6223559696, content=谢谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Mon Aug 21 07:31:47 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235575, encodeId=06c42355e532, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200814/81d08245657a4a7f9a1ef713c0ec5878/ec4b201a22194a319b1aeb171bc6bb3d.jpg, createdBy=41e02111625, createdName=1581f8c42cm, createdTime=Mon Aug 21 07:13:35 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235509, encodeId=2ad2235509b0, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Mon Aug 21 00:17:40 CST 2017, time=2017-08-21, status=1, ipAttribution=)]
    2017-08-22 1e135751m36(暂无匿称)

    前沿

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=236073, encodeId=d16a2360e3a2, content=前沿, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/03/19/68358be9323aa8e32edd53bfd17742f1.jpg, createdBy=5a191960665, createdName=1e135751m36(暂无匿称), createdTime=Tue Aug 22 17:49:05 CST 2017, time=2017-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521482, encodeId=5e7715214823e, content=<a href='/topic/show?id=0e108281e8f' target=_blank style='color:#2F92EE;'>#肿瘤免疫疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82817, encryptionId=0e108281e8f, topicName=肿瘤免疫疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=995711357332, createdName=drwjr, createdTime=Tue Aug 22 09:46:00 CST 2017, time=2017-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235692, encodeId=bbed23569209, content=免疫疗法有时对癌症患者无反应,或者癌症易复发,这可能都是T细胞疲劳造成的结果, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Mon Aug 21 13:03:23 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235669, encodeId=adfb2356692e, content=免疫学有可能的, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Mon Aug 21 11:38:59 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235660, encodeId=4923235660d9, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuCkPCv9CVFBmWOibyBArQwSeQLxvxz9OaumlaSUZjfCWTxbXduhuG2xCJUPs1nB9nd4gxZknH7IZj/0, createdBy=52281985209, createdName=damiao93, createdTime=Mon Aug 21 10:38:11 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235625, encodeId=54fc23562573, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM7GibvIBibibnnnvpajk2stlDF5oichYahI6Bia8uxeTBFoPbdoHWebyXf9eal9FNgUF2lNcrwoZicM3BvQ/0, createdBy=a3742066385, createdName=戒馋,懒,贪, createdTime=Mon Aug 21 08:13:15 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235601, encodeId=cfe8235601ab, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Mon Aug 21 07:36:59 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235596, encodeId=2c6223559696, content=谢谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Mon Aug 21 07:31:47 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235575, encodeId=06c42355e532, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200814/81d08245657a4a7f9a1ef713c0ec5878/ec4b201a22194a319b1aeb171bc6bb3d.jpg, createdBy=41e02111625, createdName=1581f8c42cm, createdTime=Mon Aug 21 07:13:35 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235509, encodeId=2ad2235509b0, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Mon Aug 21 00:17:40 CST 2017, time=2017-08-21, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=236073, encodeId=d16a2360e3a2, content=前沿, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/03/19/68358be9323aa8e32edd53bfd17742f1.jpg, createdBy=5a191960665, createdName=1e135751m36(暂无匿称), createdTime=Tue Aug 22 17:49:05 CST 2017, time=2017-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521482, encodeId=5e7715214823e, content=<a href='/topic/show?id=0e108281e8f' target=_blank style='color:#2F92EE;'>#肿瘤免疫疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82817, encryptionId=0e108281e8f, topicName=肿瘤免疫疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=995711357332, createdName=drwjr, createdTime=Tue Aug 22 09:46:00 CST 2017, time=2017-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235692, encodeId=bbed23569209, content=免疫疗法有时对癌症患者无反应,或者癌症易复发,这可能都是T细胞疲劳造成的结果, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Mon Aug 21 13:03:23 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235669, encodeId=adfb2356692e, content=免疫学有可能的, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Mon Aug 21 11:38:59 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235660, encodeId=4923235660d9, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuCkPCv9CVFBmWOibyBArQwSeQLxvxz9OaumlaSUZjfCWTxbXduhuG2xCJUPs1nB9nd4gxZknH7IZj/0, createdBy=52281985209, createdName=damiao93, createdTime=Mon Aug 21 10:38:11 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235625, encodeId=54fc23562573, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM7GibvIBibibnnnvpajk2stlDF5oichYahI6Bia8uxeTBFoPbdoHWebyXf9eal9FNgUF2lNcrwoZicM3BvQ/0, createdBy=a3742066385, createdName=戒馋,懒,贪, createdTime=Mon Aug 21 08:13:15 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235601, encodeId=cfe8235601ab, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Mon Aug 21 07:36:59 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235596, encodeId=2c6223559696, content=谢谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Mon Aug 21 07:31:47 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235575, encodeId=06c42355e532, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200814/81d08245657a4a7f9a1ef713c0ec5878/ec4b201a22194a319b1aeb171bc6bb3d.jpg, createdBy=41e02111625, createdName=1581f8c42cm, createdTime=Mon Aug 21 07:13:35 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235509, encodeId=2ad2235509b0, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Mon Aug 21 00:17:40 CST 2017, time=2017-08-21, status=1, ipAttribution=)]
    2017-08-21 随梦飞扬

    免疫疗法有时对癌症患者无反应,或者癌症易复发,这可能都是T细胞疲劳造成的结果

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=236073, encodeId=d16a2360e3a2, content=前沿, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/03/19/68358be9323aa8e32edd53bfd17742f1.jpg, createdBy=5a191960665, createdName=1e135751m36(暂无匿称), createdTime=Tue Aug 22 17:49:05 CST 2017, time=2017-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521482, encodeId=5e7715214823e, content=<a href='/topic/show?id=0e108281e8f' target=_blank style='color:#2F92EE;'>#肿瘤免疫疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82817, encryptionId=0e108281e8f, topicName=肿瘤免疫疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=995711357332, createdName=drwjr, createdTime=Tue Aug 22 09:46:00 CST 2017, time=2017-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235692, encodeId=bbed23569209, content=免疫疗法有时对癌症患者无反应,或者癌症易复发,这可能都是T细胞疲劳造成的结果, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Mon Aug 21 13:03:23 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235669, encodeId=adfb2356692e, content=免疫学有可能的, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Mon Aug 21 11:38:59 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235660, encodeId=4923235660d9, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuCkPCv9CVFBmWOibyBArQwSeQLxvxz9OaumlaSUZjfCWTxbXduhuG2xCJUPs1nB9nd4gxZknH7IZj/0, createdBy=52281985209, createdName=damiao93, createdTime=Mon Aug 21 10:38:11 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235625, encodeId=54fc23562573, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM7GibvIBibibnnnvpajk2stlDF5oichYahI6Bia8uxeTBFoPbdoHWebyXf9eal9FNgUF2lNcrwoZicM3BvQ/0, createdBy=a3742066385, createdName=戒馋,懒,贪, createdTime=Mon Aug 21 08:13:15 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235601, encodeId=cfe8235601ab, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Mon Aug 21 07:36:59 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235596, encodeId=2c6223559696, content=谢谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Mon Aug 21 07:31:47 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235575, encodeId=06c42355e532, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200814/81d08245657a4a7f9a1ef713c0ec5878/ec4b201a22194a319b1aeb171bc6bb3d.jpg, createdBy=41e02111625, createdName=1581f8c42cm, createdTime=Mon Aug 21 07:13:35 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235509, encodeId=2ad2235509b0, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Mon Aug 21 00:17:40 CST 2017, time=2017-08-21, status=1, ipAttribution=)]
    2017-08-21 flysky120

    免疫学有可能的

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=236073, encodeId=d16a2360e3a2, content=前沿, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/03/19/68358be9323aa8e32edd53bfd17742f1.jpg, createdBy=5a191960665, createdName=1e135751m36(暂无匿称), createdTime=Tue Aug 22 17:49:05 CST 2017, time=2017-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521482, encodeId=5e7715214823e, content=<a href='/topic/show?id=0e108281e8f' target=_blank style='color:#2F92EE;'>#肿瘤免疫疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82817, encryptionId=0e108281e8f, topicName=肿瘤免疫疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=995711357332, createdName=drwjr, createdTime=Tue Aug 22 09:46:00 CST 2017, time=2017-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235692, encodeId=bbed23569209, content=免疫疗法有时对癌症患者无反应,或者癌症易复发,这可能都是T细胞疲劳造成的结果, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Mon Aug 21 13:03:23 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235669, encodeId=adfb2356692e, content=免疫学有可能的, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Mon Aug 21 11:38:59 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235660, encodeId=4923235660d9, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuCkPCv9CVFBmWOibyBArQwSeQLxvxz9OaumlaSUZjfCWTxbXduhuG2xCJUPs1nB9nd4gxZknH7IZj/0, createdBy=52281985209, createdName=damiao93, createdTime=Mon Aug 21 10:38:11 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235625, encodeId=54fc23562573, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM7GibvIBibibnnnvpajk2stlDF5oichYahI6Bia8uxeTBFoPbdoHWebyXf9eal9FNgUF2lNcrwoZicM3BvQ/0, createdBy=a3742066385, createdName=戒馋,懒,贪, createdTime=Mon Aug 21 08:13:15 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235601, encodeId=cfe8235601ab, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Mon Aug 21 07:36:59 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235596, encodeId=2c6223559696, content=谢谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Mon Aug 21 07:31:47 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235575, encodeId=06c42355e532, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200814/81d08245657a4a7f9a1ef713c0ec5878/ec4b201a22194a319b1aeb171bc6bb3d.jpg, createdBy=41e02111625, createdName=1581f8c42cm, createdTime=Mon Aug 21 07:13:35 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235509, encodeId=2ad2235509b0, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Mon Aug 21 00:17:40 CST 2017, time=2017-08-21, status=1, ipAttribution=)]
    2017-08-21 damiao93

    学习了,谢谢分享

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=236073, encodeId=d16a2360e3a2, content=前沿, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/03/19/68358be9323aa8e32edd53bfd17742f1.jpg, createdBy=5a191960665, createdName=1e135751m36(暂无匿称), createdTime=Tue Aug 22 17:49:05 CST 2017, time=2017-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521482, encodeId=5e7715214823e, content=<a href='/topic/show?id=0e108281e8f' target=_blank style='color:#2F92EE;'>#肿瘤免疫疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82817, encryptionId=0e108281e8f, topicName=肿瘤免疫疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=995711357332, createdName=drwjr, createdTime=Tue Aug 22 09:46:00 CST 2017, time=2017-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235692, encodeId=bbed23569209, content=免疫疗法有时对癌症患者无反应,或者癌症易复发,这可能都是T细胞疲劳造成的结果, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Mon Aug 21 13:03:23 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235669, encodeId=adfb2356692e, content=免疫学有可能的, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Mon Aug 21 11:38:59 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235660, encodeId=4923235660d9, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuCkPCv9CVFBmWOibyBArQwSeQLxvxz9OaumlaSUZjfCWTxbXduhuG2xCJUPs1nB9nd4gxZknH7IZj/0, createdBy=52281985209, createdName=damiao93, createdTime=Mon Aug 21 10:38:11 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235625, encodeId=54fc23562573, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM7GibvIBibibnnnvpajk2stlDF5oichYahI6Bia8uxeTBFoPbdoHWebyXf9eal9FNgUF2lNcrwoZicM3BvQ/0, createdBy=a3742066385, createdName=戒馋,懒,贪, createdTime=Mon Aug 21 08:13:15 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235601, encodeId=cfe8235601ab, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Mon Aug 21 07:36:59 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235596, encodeId=2c6223559696, content=谢谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Mon Aug 21 07:31:47 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235575, encodeId=06c42355e532, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200814/81d08245657a4a7f9a1ef713c0ec5878/ec4b201a22194a319b1aeb171bc6bb3d.jpg, createdBy=41e02111625, createdName=1581f8c42cm, createdTime=Mon Aug 21 07:13:35 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235509, encodeId=2ad2235509b0, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Mon Aug 21 00:17:40 CST 2017, time=2017-08-21, status=1, ipAttribution=)]
    2017-08-21 戒馋,懒,贪

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=236073, encodeId=d16a2360e3a2, content=前沿, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/03/19/68358be9323aa8e32edd53bfd17742f1.jpg, createdBy=5a191960665, createdName=1e135751m36(暂无匿称), createdTime=Tue Aug 22 17:49:05 CST 2017, time=2017-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521482, encodeId=5e7715214823e, content=<a href='/topic/show?id=0e108281e8f' target=_blank style='color:#2F92EE;'>#肿瘤免疫疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82817, encryptionId=0e108281e8f, topicName=肿瘤免疫疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=995711357332, createdName=drwjr, createdTime=Tue Aug 22 09:46:00 CST 2017, time=2017-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235692, encodeId=bbed23569209, content=免疫疗法有时对癌症患者无反应,或者癌症易复发,这可能都是T细胞疲劳造成的结果, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Mon Aug 21 13:03:23 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235669, encodeId=adfb2356692e, content=免疫学有可能的, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Mon Aug 21 11:38:59 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235660, encodeId=4923235660d9, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuCkPCv9CVFBmWOibyBArQwSeQLxvxz9OaumlaSUZjfCWTxbXduhuG2xCJUPs1nB9nd4gxZknH7IZj/0, createdBy=52281985209, createdName=damiao93, createdTime=Mon Aug 21 10:38:11 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235625, encodeId=54fc23562573, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM7GibvIBibibnnnvpajk2stlDF5oichYahI6Bia8uxeTBFoPbdoHWebyXf9eal9FNgUF2lNcrwoZicM3BvQ/0, createdBy=a3742066385, createdName=戒馋,懒,贪, createdTime=Mon Aug 21 08:13:15 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235601, encodeId=cfe8235601ab, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Mon Aug 21 07:36:59 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235596, encodeId=2c6223559696, content=谢谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Mon Aug 21 07:31:47 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235575, encodeId=06c42355e532, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200814/81d08245657a4a7f9a1ef713c0ec5878/ec4b201a22194a319b1aeb171bc6bb3d.jpg, createdBy=41e02111625, createdName=1581f8c42cm, createdTime=Mon Aug 21 07:13:35 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235509, encodeId=2ad2235509b0, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Mon Aug 21 00:17:40 CST 2017, time=2017-08-21, status=1, ipAttribution=)]
    2017-08-21 130****4638

    学习了受益匪浅

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=236073, encodeId=d16a2360e3a2, content=前沿, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/03/19/68358be9323aa8e32edd53bfd17742f1.jpg, createdBy=5a191960665, createdName=1e135751m36(暂无匿称), createdTime=Tue Aug 22 17:49:05 CST 2017, time=2017-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521482, encodeId=5e7715214823e, content=<a href='/topic/show?id=0e108281e8f' target=_blank style='color:#2F92EE;'>#肿瘤免疫疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82817, encryptionId=0e108281e8f, topicName=肿瘤免疫疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=995711357332, createdName=drwjr, createdTime=Tue Aug 22 09:46:00 CST 2017, time=2017-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235692, encodeId=bbed23569209, content=免疫疗法有时对癌症患者无反应,或者癌症易复发,这可能都是T细胞疲劳造成的结果, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Mon Aug 21 13:03:23 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235669, encodeId=adfb2356692e, content=免疫学有可能的, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Mon Aug 21 11:38:59 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235660, encodeId=4923235660d9, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuCkPCv9CVFBmWOibyBArQwSeQLxvxz9OaumlaSUZjfCWTxbXduhuG2xCJUPs1nB9nd4gxZknH7IZj/0, createdBy=52281985209, createdName=damiao93, createdTime=Mon Aug 21 10:38:11 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235625, encodeId=54fc23562573, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM7GibvIBibibnnnvpajk2stlDF5oichYahI6Bia8uxeTBFoPbdoHWebyXf9eal9FNgUF2lNcrwoZicM3BvQ/0, createdBy=a3742066385, createdName=戒馋,懒,贪, createdTime=Mon Aug 21 08:13:15 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235601, encodeId=cfe8235601ab, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Mon Aug 21 07:36:59 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235596, encodeId=2c6223559696, content=谢谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Mon Aug 21 07:31:47 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235575, encodeId=06c42355e532, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200814/81d08245657a4a7f9a1ef713c0ec5878/ec4b201a22194a319b1aeb171bc6bb3d.jpg, createdBy=41e02111625, createdName=1581f8c42cm, createdTime=Mon Aug 21 07:13:35 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235509, encodeId=2ad2235509b0, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Mon Aug 21 00:17:40 CST 2017, time=2017-08-21, status=1, ipAttribution=)]
    2017-08-21 明月清辉

    谢谢分享,学习了

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=236073, encodeId=d16a2360e3a2, content=前沿, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/03/19/68358be9323aa8e32edd53bfd17742f1.jpg, createdBy=5a191960665, createdName=1e135751m36(暂无匿称), createdTime=Tue Aug 22 17:49:05 CST 2017, time=2017-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521482, encodeId=5e7715214823e, content=<a href='/topic/show?id=0e108281e8f' target=_blank style='color:#2F92EE;'>#肿瘤免疫疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82817, encryptionId=0e108281e8f, topicName=肿瘤免疫疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=995711357332, createdName=drwjr, createdTime=Tue Aug 22 09:46:00 CST 2017, time=2017-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235692, encodeId=bbed23569209, content=免疫疗法有时对癌症患者无反应,或者癌症易复发,这可能都是T细胞疲劳造成的结果, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Mon Aug 21 13:03:23 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235669, encodeId=adfb2356692e, content=免疫学有可能的, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Mon Aug 21 11:38:59 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235660, encodeId=4923235660d9, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuCkPCv9CVFBmWOibyBArQwSeQLxvxz9OaumlaSUZjfCWTxbXduhuG2xCJUPs1nB9nd4gxZknH7IZj/0, createdBy=52281985209, createdName=damiao93, createdTime=Mon Aug 21 10:38:11 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235625, encodeId=54fc23562573, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM7GibvIBibibnnnvpajk2stlDF5oichYahI6Bia8uxeTBFoPbdoHWebyXf9eal9FNgUF2lNcrwoZicM3BvQ/0, createdBy=a3742066385, createdName=戒馋,懒,贪, createdTime=Mon Aug 21 08:13:15 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235601, encodeId=cfe8235601ab, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Mon Aug 21 07:36:59 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235596, encodeId=2c6223559696, content=谢谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Mon Aug 21 07:31:47 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235575, encodeId=06c42355e532, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200814/81d08245657a4a7f9a1ef713c0ec5878/ec4b201a22194a319b1aeb171bc6bb3d.jpg, createdBy=41e02111625, createdName=1581f8c42cm, createdTime=Mon Aug 21 07:13:35 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235509, encodeId=2ad2235509b0, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Mon Aug 21 00:17:40 CST 2017, time=2017-08-21, status=1, ipAttribution=)]
    2017-08-21 1581f8c42cm

    学习了

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=236073, encodeId=d16a2360e3a2, content=前沿, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/03/19/68358be9323aa8e32edd53bfd17742f1.jpg, createdBy=5a191960665, createdName=1e135751m36(暂无匿称), createdTime=Tue Aug 22 17:49:05 CST 2017, time=2017-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521482, encodeId=5e7715214823e, content=<a href='/topic/show?id=0e108281e8f' target=_blank style='color:#2F92EE;'>#肿瘤免疫疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82817, encryptionId=0e108281e8f, topicName=肿瘤免疫疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=995711357332, createdName=drwjr, createdTime=Tue Aug 22 09:46:00 CST 2017, time=2017-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235692, encodeId=bbed23569209, content=免疫疗法有时对癌症患者无反应,或者癌症易复发,这可能都是T细胞疲劳造成的结果, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Mon Aug 21 13:03:23 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235669, encodeId=adfb2356692e, content=免疫学有可能的, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Mon Aug 21 11:38:59 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235660, encodeId=4923235660d9, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuCkPCv9CVFBmWOibyBArQwSeQLxvxz9OaumlaSUZjfCWTxbXduhuG2xCJUPs1nB9nd4gxZknH7IZj/0, createdBy=52281985209, createdName=damiao93, createdTime=Mon Aug 21 10:38:11 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235625, encodeId=54fc23562573, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM7GibvIBibibnnnvpajk2stlDF5oichYahI6Bia8uxeTBFoPbdoHWebyXf9eal9FNgUF2lNcrwoZicM3BvQ/0, createdBy=a3742066385, createdName=戒馋,懒,贪, createdTime=Mon Aug 21 08:13:15 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235601, encodeId=cfe8235601ab, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Mon Aug 21 07:36:59 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235596, encodeId=2c6223559696, content=谢谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Mon Aug 21 07:31:47 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235575, encodeId=06c42355e532, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200814/81d08245657a4a7f9a1ef713c0ec5878/ec4b201a22194a319b1aeb171bc6bb3d.jpg, createdBy=41e02111625, createdName=1581f8c42cm, createdTime=Mon Aug 21 07:13:35 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235509, encodeId=2ad2235509b0, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Mon Aug 21 00:17:40 CST 2017, time=2017-08-21, status=1, ipAttribution=)]
    2017-08-21 luominglian113

    学习了,谢谢分享

    0

相关资讯

未来五强抗癌药出炉!靶向和免疫疗法成新贵

靶向治疗和免疫疗法是目前癌症药物研发炙手可热的方向。据全球领先的医药市场研究机构Evaluate Pharma数据分析报告,未来5年卖得最好的5款药中,有4种是依靠靶向和免疫疗法所研发的。“免疫疗法是目前治疗肿瘤的主要方式之一,药物是免疫疗法的中坚力量,常见的如PD-1/PD-L1抑制剂类药物。”首都医科大学附属北京世纪坛医院肿瘤中心主任任军告诉记者,以Keytruda为代表抗肿瘤的靶向药物是精准

JCO:更新肺癌治疗指南!基因检测要做,免疫疗法被“写进”一线治疗

对于IV型非小细胞肺癌患者,应根据患者癌症的不同类型提供什么样的全身治疗方案?2017年8月14日,美国临床肿瘤协会(ASCO)于《临床肿瘤学杂志》(JCO)在线更新了临床实践指南,为我们提供了相关推荐。据悉,上一次更新还是在2015年,这些建议是基于患者已经做过EGFR/ALK/ROS1基因检测,同时免疫疗法也被“写进”了一线治疗。

张锋教授Nature发文,CRISPR技术找到了癌症免疫疗法关键基因!

要说近年来癌症领域取得的最大突破,那莫过于免疫疗法了。一些原本等同于死刑判决的恶性癌症,在免疫疗法的作用下,竟能连续10多年不复发,这近乎达到了治愈的效果,堪称奇迹。 但免疫疗法也不是万能的。肿瘤细胞一直在快速突变,而有些突变会让免疫疗法失效。目前我们知道,B2M、JAK1与JAK2基因一旦发生突变失活,就会让免疫疗法失去应有的作用。

Nature:惊人发现!“重磅抗癌药”CDK4/6抑制剂竟然也是免疫疗法

自2015年全球首个CDK4/6抑制剂获批以来,年销售超过20亿美元的“成绩”让这类抗癌药物备受瞩目。近日,发表在Nature杂志上的一项重要成果发现了CDK4/6抑制剂一种意外的机制——激活抗肿瘤免疫力。这一结论与先前的一些观点恰恰相反,且证明了这类药物也是一种免疫疗法。

Nature:免疫疗法关键靶点PD-L1竟有不为人知的“帮手”

PD-1/PD-L1无疑是癌症免疫治疗领域最热门的一对靶点。8月16日,在线发表于Nature杂志上的两篇论文同时发现了调节PD-L1的一个先前未知的分子——CMTM6。有趣的是,两个科学家团队利用了完全不同的方法得出了相同的结论。魔剪CRISPR又在其中一篇论文中立了一功。

Cell:免疫疗法大牛James Allison全新:PD-1抗体与CTLA-4抗体原来如此不同

MD安德森癌症中心的James P. Allison教授是癌症免疫疗法的先驱之一,也被称“CTLA-4抗体Yervoy之父”。去年,他还荣获了有着诺奖风向标之称的汤森路透“引文桂冠奖”。近日,他带领的研究小组在Cell杂志上发表了一项新成果,揭开了CTLA-4抗体和PD-1抗体这两类癌症免疫疗法不同的细胞机制。